Abstract:
© Bionika Media Ltd. Objective. To evaluate the efficacy and safety of an agent containing ethinylestradiol (EE) in combination with chlormadinone acetate (CMA) in contraceptive-needing patients within the framework of the pharmacological epidemiological observational project. Subjects and methods. The study enrolled 161 female patients needing contraception. All patients had no contraindications to combined oral contraceptives (COCs) and conditions in which COCs should be used with caution. All the women took EE in combination with CMA in a 21/7 cyclic regimen for contraception. To evaluate its efficacy and safety, the occurrence of pregnancy was assessed within 6 months of EE/CMA intake. To estimate safety parameters, the changes in body weight, blood pressure, and hemostatic parameters that characterized the risk of hypercoagulation disorders were assessed. Results. During the follow-up, no pregnancy occurred in the patients included in the study. Significant changes in weight gain, blood pressure, and improvement in the blood coagulation potential were not observed. The hormonal contraceptive with CMA demonstrated an additional positive effect on the women’s emotional state. Conclusion. The findings may conclude that EE in combination with CMA is highly effective and safe and may also highlight its additional positive effects.
